UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans – Endpoints News
Endpoints News |
UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans
Endpoints News The UK’s pharma price watchdog NICE has sanctioned coverage of GlaxoSmithKline’s gene therapy Strimvelis for “bubble baby” syndrome, which costs about $700,000 for the once-and-done therapy. About three babies a year are born with ADA-SCID in the … |
|
Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack
Seeking Alpha CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. NVS will maintain a significant leading role in CAR-T engineering with NTLA’s CRISPR technologies … |
|
Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack
Seeking Alpha CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. NVS will maintain a significant leading role in CAR-T engineering with NTLA’s CRISPR technologies … |
The Guardian |
Gene therapy for ‘bubble baby’ syndrome approved on NHS …
The Guardian GlaxoSmithKline’s Strimvelis is the first such treatment to be funded in the UK. NHS to fund gene therapy for ‘bubble babies’Telegraph.co.uk Britain backs GSK’s gene therapy for ‘bubble boy’ syndromeReuters GSK picks up NICE recommendation for Strimvelis, a €594000 gene therapyFiercePharma PharmaTimes –NICE –pharmaphorum all 19 news articles » |
U.S. News & World Report |
T Cells Take on Cancer
U.S. News & World Report In addition to checkpoint inhibitors, a type of immunotherapy showing promise is chimeric antigen receptor T-cell therapy, in which T cells, a key part of the immune system, are genetically modified in the lab to target the person’s specific cancer … |